A multicenter trial for evaluating the dose safety of anti-PD-L1 (BMS-936559 of Bristol–Myers Squibb) in patients with sepsis has recently been completed and results of the study are awaited (ClinicalTrial.gov# NCT02576457). The gene discussed is CD274; the disease is Sepsis.